Crystalline forms of the sodium salt of (4-{4-[5-(6-trifluoromethyl-pyridin-3-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid

US8829194B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Paul Allen Sutton · Parsippany, US
• Michael John Girgis · Richmond, US
• Jessica Liang · Annandale, US
• Mahavir Prashad · East Hanover, US
• Edwin Bernard Villhauer · Morristown, US

Key dates

• Filing date: Oct 5, 2011
• Grant date: Sep 9, 2014
• Expiry date: Oct 5, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D213/72
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to novel crystalline forms of (4-{4-[5-(6-Trifluoromethyl-pyridin-3-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid, sodium and their use in the treatment or prevention of a condition or a disorder associated with DGAT1 activity in animals, particularly humans. It also relates to processes for making such novel crystalline forms.